Raloxifene HCl*
-
API Product :
Raloxifene HCl*
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Cardiac therapy; Cytostatic Hormone Therapy; Lipid-regulating/anti-atheroma preparations; Other Drugs For Disorders Of The Musculo-Skeletal System; Sex hormones and products with similar desired effects, systemic action only
-
Originator :
Eli Lilly
-
CAS No. :
84449-90-1
-
Trade Name. :
EVISTA
-
Molecular Weight :
473.584 g/mol
-
Molecular Formula :
C28H27NO4S
Application
Raloxifene hydrochloride is a second generation selective estrogen receptor modulator (SERM) used to preventosteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
General Description
Raloxifene, developed by Eli Lilly in 1997 and sold under the brand name Evista among others, is a medication which is used in the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer.[3][4][5] It is taken by mouth.